17,261 trials
Plasmodium Falciparum Infection
Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 28 (ACPR28) — 80.8; 90.3; 90.9…
Breast Cancer
Primary: Disease-free Survival (DFS) — 89.8; 83.8 Percentage of participants who survived — p=0.18
Hepatocellular Carcinoma
Primary: Overall Survival (OS): Number of Events — 15; 58; 31 Participants with events — p=0.837
Male Hypogonadism
Primary: Mean T Cavg25 Following Meals Containing Various Amounts of Dietary Fat Compared to Normal Fat Diet — 6.38; 6.73; 6.88; 7.00 ng/dL — p=0.0025
Liver Fibrosis
Primary: Median Liver Stiffness Value — 7.70; 6.90 kPa — p=0.043
Parkinson Disease
Primary: Safety Adverse Events — 0; 0; 0; 0 participants
Osteoarthritis, Hip
Primary: Number of Patients With Successful Study Drug Administrations — 12 Participants
Hemorrhagic Fever With Renal Syndrome
Primary: Number of Participants With Seroconversion of HTNV and PUUV Using PsVNA50 — 1; 1; 1; 2 Participants
Vitiligo
Primary: Mean Change From Baseline in Facial Depigmentation in the AOI (Area of Interest) Based on Canfield 2-D Photographic Analysis From Baseline to Week 24 — 2.0 score on a…
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in FEV1 to Day 7 - ITT Population — 0.084; 0.115; 0.057 litre — p=0.012
Acute Myeloid Leukemia
Primary: Number of Participants With Complete Remission With or Without Incomplete Platelet Recovery — 1 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Pain
Primary: Pain Score 8 Hours Post-operativley — 2.5; 1.8; 1.06 units on a scale
Presbyopia
Primary: Change in Binocular Distance-corrected Near Visual Acuity (DCNVA) From Baseline — 6.1; 4.5 number of letters read correctly — p=0.1832
Psoriasis
Primary: The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) on Day 85…